AmSurg Given “Neutral” Rating at Zacks (AMSG)
Zacks’ analyst wrote, “AmSurg’s fourth-quarter EPS of $0.49 was up 6.5% year over year. Although it missed the Zacks Consensus Estimate of $0.02, EPS remained within the company’s guidance range. Revenues increased 10% to $244.2 million. Double-digit sales growth in the past several quarters came on the back of new centers and improved same-center sales. We are also impressed with the company’s improved price-volume mix leading to the 7th consecutive quarter of same-center growth. This reflects its promising position in the market. Yet several challenges remain, such as reimbursement issues and economic uncertainty. Accordingly, we remain Neutral on the stock.”
AmSurg (NASDAQ: AMSG) traded up 1.13% on Friday, hitting $33.19. AmSurg has a 1-year low of $25.00 and a 1-year high of $33.24. The stock’s 50-day moving average is currently $31.1. The company has a market cap of $1.066 billion and a price-to-earnings ratio of 16.58.
Separately, analysts at Piper Jaffray raised their price target on shares of AmSurg to $32.00 in a research note to investors on Tuesday, February 26th.
AmSurg Corp. is engaged in developing, acquiring and operating ambulatory surgery centers (NASDAQ: AMSG) in partnership with physicians throughout the United States.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.